KR101174672B1 - 항증식제로서의 피리도- 및 피리미도피리미딘 유도체 - Google Patents

항증식제로서의 피리도- 및 피리미도피리미딘 유도체 Download PDF

Info

Publication number
KR101174672B1
KR101174672B1 KR1020067014283A KR20067014283A KR101174672B1 KR 101174672 B1 KR101174672 B1 KR 101174672B1 KR 1020067014283 A KR1020067014283 A KR 1020067014283A KR 20067014283 A KR20067014283 A KR 20067014283A KR 101174672 B1 KR101174672 B1 KR 101174672B1
Authority
KR
South Korea
Prior art keywords
alkyl
het
formula
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067014283A
Other languages
English (en)
Korean (ko)
Other versions
KR20060126716A (ko
Inventor
에디 쟝 에드가르드 프레이니
마크 윌렘스
피에르 헨리 스토르크
버지니에 소피에 퐁셀레트
에멜렌 크리스토프 반
피터 야코부스 조하네스 안토니우스 부이진스터스
워너 콘스탄트 조한 엠브레치스
티모시 피에트로 서렌 페레라
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20060126716A publication Critical patent/KR20060126716A/ko
Application granted granted Critical
Publication of KR101174672B1 publication Critical patent/KR101174672B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020067014283A 2003-12-18 2006-07-14 항증식제로서의 피리도- 및 피리미도피리미딘 유도체 Expired - Lifetime KR101174672B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51062 2003-12-18
EPPCT/EP03/51058 2003-12-18
EP0351062 2003-12-18
EP0351058 2003-12-18
PCT/EP2004/053501 WO2005058913A1 (en) 2003-12-18 2004-12-15 Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents

Publications (2)

Publication Number Publication Date
KR20060126716A KR20060126716A (ko) 2006-12-08
KR101174672B1 true KR101174672B1 (ko) 2012-08-20

Family

ID=34702160

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067014283A Expired - Lifetime KR101174672B1 (ko) 2003-12-18 2006-07-14 항증식제로서의 피리도- 및 피리미도피리미딘 유도체

Country Status (18)

Country Link
US (3) US7799772B2 (enExample)
EP (1) EP1697384B1 (enExample)
JP (1) JP4936897B2 (enExample)
KR (1) KR101174672B1 (enExample)
AR (1) AR046957A1 (enExample)
AU (1) AU2004298448B2 (enExample)
CA (1) CA2549869C (enExample)
DE (1) DE602004012891T2 (enExample)
EA (1) EA013904B1 (enExample)
ES (1) ES2305887T3 (enExample)
IL (1) IL176357A (enExample)
MX (1) MXPA06007017A (enExample)
MY (1) MY146415A (enExample)
NO (1) NO337701B1 (enExample)
NZ (1) NZ547794A (enExample)
TW (1) TWI347187B (enExample)
UA (1) UA83881C2 (enExample)
WO (1) WO2005058913A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799772B2 (en) 2003-12-18 2010-09-21 Janssen Pharmaceutica N.V. Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
PH12012501003B1 (en) * 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
EA014779B1 (ru) 2006-07-13 2011-02-28 Янссен Фармацевтика Н.В. Производные хиназолина в качестве mtki
KR20090089849A (ko) * 2006-10-27 2009-08-24 얀센 파마슈티카 엔.브이. Ｖｅｇｆｒ３ 저해제로서의 마크로사이클릭 퀴나졸린 유도체
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
ES2435454T3 (es) * 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
EP2185562B1 (en) * 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
GB0921203D0 (en) 2009-12-03 2010-01-20 Al Lamee Kadem G Drugs formulations for cardiovascular stents
AU2011256380C1 (en) 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
WO2012125668A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
ES2583477T3 (es) * 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2
CA2887203A1 (en) 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. 2,3-(hetero)aryl substituted pyridinyl compounds and their use as gdf-8 inhibitors
US9861635B2 (en) * 2013-05-06 2018-01-09 Merck Patent Gmbh Macrocycles as kinase inhibitors
ES2945905T3 (es) * 2014-02-07 2023-07-10 Exithera Pharmaceuticals Inc Compuestos y composiciones terapéuticos
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
EP3699181B1 (en) 2014-11-16 2023-03-01 Array Biopharma, Inc. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
MX2018004109A (es) 2015-10-05 2018-09-27 Univ Columbia Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3800189T3 (fi) 2016-05-18 2023-07-31 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110386945B (zh) * 2018-04-18 2021-09-28 广州白云山医药集团股份有限公司白云山制药总厂 一种大环类激酶抑制剂

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (enExample) 1956-06-11
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
NZ181256A (en) 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4126688A (en) * 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives
US4442278A (en) * 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP0892789B2 (en) * 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
PL341762A1 (en) 1997-12-24 2001-05-07 Vertex Pharma Precursors of aspartil protease inhibitors
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
ES2191462T3 (es) * 1998-10-01 2003-09-01 Astrazeneca Ab Derivados de quinolina y quinazolina y su uso como inhibidores de enfermedades mediadas por citoquinas.
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
AU5783300A (en) * 1999-07-09 2001-01-30 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
DE50012136D1 (en) 1999-08-27 2006-04-13 Boehringer Ingelheim Pharma Substituierte indolinone als tyrosinkinase inhibitoren
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
KR100815681B1 (ko) * 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
DE60215178T2 (de) * 2001-07-16 2007-08-23 Astrazeneca Ab Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
MXPA04008356A (es) 2002-02-28 2005-09-12 Univ Temple (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas con un grupo amino y en la posicion 4 para tratar trastornos poliferativos.
ATE557008T1 (de) 2002-03-30 2012-05-15 Boehringer Ingelheim Pharma 4- ( n-phenylamino ) -chinazoline/chinoline als tyrosinkinaseinhibitoren
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2004004732A1 (en) 2002-07-09 2004-01-15 Astrazeneca Ab Quinazoline derivatives for use in the treatment of cancer
EP1546121B1 (en) 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
CA2493908A1 (en) 2002-08-08 2004-02-19 Smithkline Beecham Corporation Thiophene compounds
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
JPWO2004043936A1 (ja) 2002-11-14 2006-03-09 協和醗酵工業株式会社 Ｐｌｋ阻害剤
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
US7799772B2 (en) * 2003-12-18 2010-09-21 Janssen Pharmaceutica N.V. Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
MXPA06007018A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolino con actividad anti-proliferativa.
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
EA017545B1 (ru) 2005-06-30 2013-01-30 Янссен Фармацевтика Н.В. Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3
JP2007135441A (ja) 2005-11-16 2007-06-07 Kenichi Mikiya 新規タンパク質及びそれをコードする遺伝子
PH12012501003B1 (en) 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
EA014779B1 (ru) 2006-07-13 2011-02-28 Янссен Фармацевтика Н.В. Производные хиназолина в качестве mtki
US20080219975A1 (en) * 2006-10-27 2008-09-11 Timothy Pietro Suren Perera Vegfr3 inhibitors
KR20090089849A (ko) 2006-10-27 2009-08-24 얀센 파마슈티카 엔.브이. Ｖｅｇｆｒ３ 저해제로서의 마크로사이클릭 퀴나졸린 유도체
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
EP2185562B1 (en) * 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
JP5480824B2 (ja) * 2008-03-10 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐｌｋキナーゼ阻害剤としての４−アリール−２−アニリノ−ピリミジン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
해당사항없음

Also Published As

Publication number Publication date
AU2004298448B2 (en) 2010-09-09
TWI347187B (en) 2011-08-21
DE602004012891D1 (de) 2008-05-15
US8933067B2 (en) 2015-01-13
TW200528111A (en) 2005-09-01
NO337701B1 (no) 2016-06-06
US8772272B2 (en) 2014-07-08
EP1697384B1 (en) 2008-04-02
WO2005058913A1 (en) 2005-06-30
AU2004298448A1 (en) 2005-06-30
JP4936897B2 (ja) 2012-05-23
EA013904B1 (ru) 2010-08-30
JP2007514712A (ja) 2007-06-07
UA83881C2 (en) 2008-08-26
KR20060126716A (ko) 2006-12-08
NO20063323L (no) 2006-07-18
CA2549869A1 (en) 2005-06-30
EA200601177A1 (ru) 2006-10-27
US7799772B2 (en) 2010-09-21
MY146415A (en) 2012-08-15
EP1697384A1 (en) 2006-09-06
CA2549869C (en) 2015-05-05
IL176357A (en) 2011-08-31
MXPA06007017A (es) 2006-08-31
US20130231353A1 (en) 2013-09-05
HK1099293A1 (zh) 2007-08-10
DE602004012891T2 (de) 2009-04-09
ES2305887T3 (es) 2008-11-01
US20070078132A1 (en) 2007-04-05
US20100173913A1 (en) 2010-07-08
IL176357A0 (en) 2006-10-05
NZ547794A (en) 2009-11-27
AR046957A1 (es) 2006-01-04

Similar Documents

Publication Publication Date Title
KR101174672B1 (ko) 항증식제로서의 피리도- 및 피리미도피리미딘 유도체
US9040511B2 (en) 3-cyano-quinoline derivatives with antiproliferative activity
KR101320431B1 (ko) Ｍｔｋｉ 퀴나졸린 유도체
CN100506823C (zh) 作为抗增殖药剂的吡啶并嘧啶和嘧啶并嘧啶衍生物
HK1099293B (en) Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
BRPI0417534B1 (pt) derivados de pirido- e pirimidopirimidina como agentes antiproliferativos, intermediários, seu processo de preparação e composição farmacêutica que os compreende e uso
HK1095742B (en) 3-cyano-quinoline derivatives with antiproliferative activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060714

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110916

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120517

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120810

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120813

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150716

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150716

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160720

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170719

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180718

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190718

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190718

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200715

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220718

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230705

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20240703

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20250615

Termination category: Expiration of duration